CytoSurge AG developed FluidFM®, the only technology enabling access, perturbation, and analysis of the same living cell over time. The FluidFM OMNIUM platform allows repeated single-cell biopsies for temporal RNA-seq. The company's CellEDIT service delivers vector-free, precise genome engineering.
Products, services, technology
The FluidFM OMNIUM platform enables precise, non-destructive single-cell injection and extraction, compatible with RNA analysis and gene editing. Based on FluidFM®, CellEDIT delivers vector-free, stoichiometrically controlled KOs, KIs, and multiplex genome edits -even in hard-to-transfect cells.
Cooperation possibilities
We actively seek partners to advance the CellEDIT Service and Live-seq applications, along with investors to fuel innovation and growth.
- https://www.cytosurge.com
- +41 77 267 08 33
- Send an email
- Erica Fiorini
